← Back to list
Systemic Lupus Erythematosus (SLE) & Lupus Nephritis (LN)
Effective date
Not stated in the notice
Identified
Jun 20, 2026
Summary
Benlysta (belimumab) requires prior authorization for active systemic lupus erythematosus (SLE) and active lupus nephritis (LN). Lupkynis (voclosporin) and Saphnelo (anifrolumab-fnia) are considered not medically necessary because other formulary alternatives are covered by the plan for these conditions. The most recent review, dated 02/24/2026, revised the medically necessary criteria for members with active SLE without active lupus nephritis.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.
Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.
What to do
Action · 11 steps
01REQUIREMENTS: Billing team: Confirm the drug is covered under the member's benefit with a formulary drug search on the member ID, and get prior authorization before billing Benlysta (belimumab).
02For SLE without active lupus nephritis, the member must be 5 years of age or older, must be currently receiving and continuing standard SLE treatment with Benlysta, must have had an inadequate response to hydroxychloroquine or have a hypersensitivity or FDA-labeled contraindication to it, and must have had an inadequate response to a corticosteroid or immunosuppressive agent or a documented intolerance, hypersensitivity, or FDA-labeled contraindication to all standard SLE treatments.
03For active lupus nephritis, the member must be 5 years of age or older, have a clinical diagnosis of SLE, have LN Class III, Class IV, or Class V confirmed by kidney biopsy, and be receiving or about to receive standard lupus nephritis therapy.
04For both, the member must not have had severe active central nervous system lupus requiring therapeutic intervention within the past 60 days, the prescriber must be a specialist or have consulted one (rheumatologist or nephrologist), Benlysta must not be used with another immunomodulatory agent (TNF inhibitors, JAK inhibitors, or IL-4 inhibitors), there must be no FDA-labeled contraindication, and the dosage must be within the program quantity limits.
05Initial approval is for 6 months.
06Renewal requires prior approval through the BCBSMS PA process and documented clinical improvement, and renewal approval is for 12 months.
07Samples given to an individual do not count as current or stable therapy.
08Medication failure is judged from pharmacy claims data over the preceding twelve months, so for a new member, the member or requesting provider must obtain pharmacy records and submit them to BCBSMS upon request, and medical records listing prescribed medications are not sufficient.
09Benlysta is investigational for other indications, including severe active central nervous system lupus and use in combination with other biologics.
10Services related to delivery or administration of a medication that was not approved through the BCBSMS PA review process will be considered not medically necessary.
11Services not documented as medically necessary will not be paid.
Codes mentioned
J0490J0491A18.4D68.312D68.62L93.0L93.1L93.2M32.0M32.10M32.11M32.12M32.13M32.14M32.15M32.19M32.8M32.9
Original notice
Systemic Lupus Erythematosus (SLE) & Lupus Nephritis (LN)
bcbsms.com · Always check the source before changing claims.